BioDelivery Sciences International Inc. (BDSI) Given a $7.00 Price Target at Roth Capital


The firm presently has a "buy" rating on the specialty pharmaceutical company's stock. Roth Capital's price target points to a potential upside of 278.38% from the stock's current price.



from Biotech News